These findings suggest that therapeutically targeting both IL-8 and IL-24 will not only aid in limiting the progression of COPD but can also prove as a potential therapy in the management of various other inflammatory conditions. This evidence concerns the gene CXCL8 and chronic obstructive pulmonary disease.